Overview

Effect of Testofen on Erectile Function in an Adult Male Population

Status:
Not yet recruiting
Trial end date:
2023-08-31
Target enrollment:
0
Participant gender:
Male
Summary
This is a double blind, randomised, placebo-controlled clinical study with a 12-week participation and 3 groups (2 active groups and 1 placebo group) designed to monitor erectile function symptom severity and the effect Testofen may have on improving erectile function, sexual function, and quality of life.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
RDC Clinical Pty Ltd
Criteria
Inclusion Criteria:

- Healthy male adults aged 40-75 years

- Currently in a sexual relationship

- Males with reduced erectile function (Score of <25 on IIEF)

- BMI ≤ 35

- Able to provide informed consent

- Agree not to change current diet and exercise program while enrolled in this trial

- Agree not to undertake another clinical trial while enrolled in this trial

Exclusion Criteria:

- History of prostate surgery and/or trauma

- Receiving/prescribed treatment for erectile dysfunction, including oral medications,
vacuum devices, constrictive devices, injections, or urethral suppositories

- Receiving/prescribed treatment to increase/decrease testosterone levels e.g.
androgens/anti androgens

- Receiving/prescribed treatment to increase/decrease nitrate or nitric oxide levels

- Unstable or serious illness (e.g. serious mood disorders, neurological disorders such
as MS, kidney disease, liver disease, heart conditions, diabetes, hormone production
disorders)*

- All current malignancies (excluding BCC) or chemotherapy and/or radiotherapy treatment
for malignancy within the previous 2 years

- Receiving/prescribed [e.g., Coumadin or Marevan (warfarin), heparin, dalteparin,
enoxaparin) or other anticoagulation therapy (e.g., thromboembolectomy or the use of
vena cava filters)

- Active smokers, nicotine use, alcohol, or drug (prescription or illegal substances)
abuse

- Chronic past and/or current alcohol use (>14 alcoholic drinks week)

- Allergic to any of the ingredients in the active or placebo formula

- Any condition which in the opinion of the investigator makes the participant
unsuitable for inclusion

- Participants who have participated in any other related clinical study during the past
1 month

a Any participant reporting having been told by their doctor that they have an under or
over production of hormones (e.g., testosterone).

*An unstable illness is any illness that is currently not being treated with a stable dose
of medication or is fluctuating in severity. A serious illness is a condition that carries
a risk of mortality, negatively impacts quality of life and daily function and/or is
burdensome in symptoms and/or treatments.